CSPC Pharmaceutical Group (HKG:1093) obtained approval from China's National Medical Products Administration to conduct clinical trials of SYS6017, a Friday Hong Kong bourse filing said.
The drug is designed to prevent herpes zoster infections, according to the pharmaceutical company.